{"product_id":"irmd-vrio-analysis","title":"IRadimed Corporation (IRMD): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs the competitive edge of IRadimed Corporation (IRMD) truly sustainable? Our deep-dive VRIO analysis cuts straight to the core, evaluating whether its current resources possess the necessary Value, Rarity, Inimitability, and Organization to secure long-term market dominance. Discover the critical strengths - and potential vulnerabilities - that define its future success right below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIRadimed Corporation (IRMD) - VRIO Analysis: Proprietary MRI-Compatible IV Pump Technology (MRidium®)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at a core asset for IRadimed Corporation: the MRidium® technology. This isn't just another medical device; it’s a specialized tool that solves a fundamental safety conflict in modern diagnostics. My take, based on their recent performance, is that this technology provides a clear, defensible advantage right now.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Non-Negotiable Safety and Premium Placement\u003c\/h3\u003e\n\u003cp\u003eThe Value here is straightforward: the MRidium® pump enables critical fluid delivery inside the MRI suite. Because conventional pumps pose a projectile risk or cause image artifacts due to magnetic interference, this capability is a non-negotiable safety feature for many procedures. This necessity allows IRadimed Corporation to command premium pricing and secure market placement where others simply cannot operate. Look at the results: Q3 2025 revenue hit $21.2 million, a 16% jump year-over-year, showing customers are willing to pay for this essential function.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: The company raised its full-year 2025 revenue guidance to between $82.5 million and $83.5 million, demonstrating the sustained demand for this high-value solution.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: The Non-Magnetic Edge\u003c\/h3\u003e\n\u003cp\u003eWhile other firms like B. Braun and Fresenius Kabi are in the broader MRI-compatible pump market, IRadimed Corporation’s MRidium® system is specifically engineered as a \u003cstrong\u003enon-magnetic\u003c\/strong\u003e system, often utilizing non-ferrous motors. This is rare because building a pump that is truly non-magnetic, rather than just shielded, requires a different, more complex engineering path. For now, they appear to be the only provider with this specific, fully non-magnetic IV infusion pump system ready for widespread clinical use. What this estimate hides is the exact number of MRI suites that require a non-magnetic solution versus one that can use magnetic-resistant technology.\u003c\/p\u003e\n\u003cp\u003eThe strength of this rarity is reflected in their operational metrics:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQ3 2025 MRI IV Pump Sales (3860 model) grew 20% year-over-year.\u003c\/li\u003e\n\u003cli\u003eThe backlog for pump systems is at an all-time high.\u003c\/li\u003e\n\u003cli\u003eAnticipated price increase for the new 3870 model is 10% to 14%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability: Deep Engineering and Regulatory Moats\u003c\/h3\u003e\n\u003cp\u003eImitating this technology is difficult. It’s not just about copying a design; it requires deep, specialized engineering knowledge in electromagnetics and material science to create a device that is both safe and effective inside an MRI bore. Plus, you have to clear the FDA hurdle. The recent FDA clearance for the next-generation 3870 IV Infusion Pump in May 2025 underscores this regulatory barrier. Competitors face a steep learning curve and significant time investment to replicate the MRidium®'s performance characteristics.\u003c\/p\u003e\n\u003cp\u003eThe difficulty of imitation creates a high barrier to entry:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eImitability Factor\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialized Engineering\u003c\/td\u003e\n\u003ctd\u003eHigh Difficulty\u003c\/td\u003e\n\u003ctd\u003eRequires non-ferrous motor design and integration.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Approval\u003c\/td\u003e\n\u003ctd\u003eSignificant Hurdle\u003c\/td\u003e\n\u003ctd\u003eFDA 510(k) clearance obtained for the 3870 system in 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime to Market\u003c\/td\u003e\n\u003ctd\u003eLong\u003c\/td\u003e\n\u003ctd\u003eYears of R\u0026amp;D needed to catch up to the current product generation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eOrganization: Strong Execution and Future Focus\u003c\/h3\u003e\n\u003cp\u003eIRadimed Corporation is organized to exploit this advantage. They just completed the move into a new, fully operational Orlando facility, which directly addresses capacity constraints and positions them to meet accelerating demand. Their organizational strength is evident in their commitment to product evolution and shareholder returns.\u003c\/p\u003e\n\u003cp\u003eKey organizational evidence includes:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew facility fully operational as of Q3 2025.\u003c\/li\u003e\n\u003cli\u003eRegular quarterly cash dividend declared at $0.17 per share for Q4 2025.\u003c\/li\u003e\n\u003cli\u003eLimited commercial shipments of the 3870 system starting in December 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThey are definitely set up to capitalize on the upcoming replacement cycle.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Sustained Superiority\u003c\/h3\u003e\n\u003cp\u003eThe combination of a high-value, rare, and difficult-to-imitate asset, supported by a strong organizational structure ready for scale, results in a \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e. The specialized nature of the MRidium® technology, coupled with the time and capital required for regulatory approval, creates a durable moat. The expected domestic pump device revenue alone, driven by the 3870 launch, could jump from an anticipated $28 million in 2025 to nearly $50 million just from pumps.\u003c\/p\u003e\n\u003cp\u003eThis isn't a temporary lead; it’s structural.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIRadimed Corporation (IRMD) - VRIO Analysis: Proprietary MRI-Compatible Patient Monitoring Technology (3880 System)\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis below focuses on the competitive implications of the IRadimed 3880 System based on the VRIO framework.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eValue: Provides uninterrupted, accurate vital signs monitoring (ECG, SpO2, CO2, BP) during MRI, directly improving patient safety and reducing scan time.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe system's design supports continuity of care, decreasing the amount of time critically ill patients are away from critical care units by allowing the monitor to travel with the patient from the unit to the MRI and back. \u003cstrong\u003eUninterrupted\u003c\/strong\u003e monitoring is achieved through its multi-parameter capabilities.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eWireless ECG with IRadimed dynamic gradient filtering.\u003c\/li\u003e\n\u003cli\u003eWireless SpO2 monitoring utilizing Masimo® algorithms.\u003c\/li\u003e\n\u003cli\u003eNon-Magnetic EtCO2 with waveform fill.\u003c\/li\u003e\n\u003cli\u003eInvasive and non-invasive blood pressure monitoring.\u003c\/li\u003e\n\u003cli\u003eFiber Optic patient temperature measurements.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eRarity: High; the 3880 system operates dependably in magnetic fields up to 30,000 gauss, a rare capability.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe capability to operate dependably in high magnetic fields is a rare characteristic in patient monitoring equipment.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTechnical Parameter\u003c\/th\u003e\n\u003cth\u003eSpecification\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMagnetic Field Limit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30,000 Gauss\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMRI System Compatibility\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e0.5 to 3.0 Tesla\u003c\/strong\u003e MRI Systems\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWireless PODS SAR Limit\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e≤4 W\/kg\u003c\/strong\u003e whole body average SAR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eImitability: Difficult; requires significant R\u0026amp;D investment and regulatory navigation to replicate the multi-parameter, non-magnetic design.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eReplication requires overcoming substantial technical hurdles related to non-magnetic component engineering and navigating the regulatory pathways for such specialized medical devices.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization: Strong; the product's compact, lightweight design facilitates easy transport, which supports efficient hospital workflow.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe organizational structure supports the product's efficiency gains, contributing to the company's financial performance. The company reported record revenue of \u003cstrong\u003e$21.2 million\u003c\/strong\u003e for the third quarter of 2025, a \u003cstrong\u003e16%\u003c\/strong\u003e increase year-over-year, and raised its full-year 2025 revenue guidance to between \u003cstrong\u003e$82.5 million\u003c\/strong\u003e and \u003cstrong\u003e$83.5 million\u003c\/strong\u003e. The gross profit margin was maintained at a strong \u003cstrong\u003e76.1%\u003c\/strong\u003e in Q1 2025. The company also maintains a regular quarterly cash dividend of \u003cstrong\u003e$0.17\u003c\/strong\u003e per share.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCompact, lightweight design allows for single staff member transport.\u003c\/li\u003e\n\u003cli\u003eIntegrated POD charging bays eliminate the need for external chargers and battery swaps.\u003c\/li\u003e\n\u003cli\u003eExtended battery life for Wireless PODS lasting greater than \u003cstrong\u003e12 hours\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Sustained; this specialized monitoring capability is a core differentiator in high-acuity imaging centers.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe combination of high magnetic field tolerance and integrated workflow efficiencies creates a sustained advantage over traditional monitoring solutions.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIRadimed Corporation (IRMD) - VRIO Analysis: Niche Market Leadership and Brand Recognition\n\u003c\/h2\u003e\n\u003ch3\u003eValue: Establishes IRADIMED CORPORATION as the default, trusted specialist in the high-risk MRI-compatible device niche.\u003c\/h3\u003e\n\u003cp\u003e\nIRADIMED CORPORATION is the only known provider of a non-magnetic intravenous (IV) infusion pump system and non-magnetic patient vital signs monitoring systems designed for use during MRI procedures.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFirst non-magnetic system introduced in \u003cstrong\u003e2005\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe 3880 system operates dependably in magnetic fields up to \u003cstrong\u003e30,000 gauss\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe MRidium® 3870 IV Infusion Pump System received FDA 510(k) clearance in \u003cstrong\u003eMay 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$21.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecord, \u003cstrong\u003e16%\u003c\/strong\u003e increase Year-over-Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecord, \u003cstrong\u003e11%\u003c\/strong\u003e increase Year-over-Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsecutive Quarters of Record Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMRI-Compatible IV Infusion Pump Systems Market Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 381.16 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2025 Projection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-Magnetic Systems Market Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e64.77%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity: Moderate; while others may try, being the established leader with proven safety records is rare.\u003c\/h3\u003e\n\u003cp\u003e\nThe company has maintained a first-mover advantage in the non-magnetic infusion pump segment since \u003cstrong\u003e2005\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNon-magnetic systems held \u003cstrong\u003e64.77%\u003c\/strong\u003e market share in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Gross Profit Margin: \u003cstrong\u003e78%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ1 2025 Gross Profit Margin: \u003cstrong\u003e76.1%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability: Difficult; brand trust in medical devices is built over years of successful use and regulatory compliance.\u003c\/h3\u003e\n\u003cp\u003e\nThe patented non-magnetic ultrasonic motor technology in the MRidium® systems represents a significant barrier.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 GAAP Diluted EPS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.43\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e8%\u003c\/strong\u003e Year-over-Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 GAAP Diluted EPS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.37\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e16%\u003c\/strong\u003e Year-over-Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e10%\u003c\/strong\u003e Year-over-Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eOrganization: Strong; reflected in their ranking as 24th on Forbes' list of America's Most Successful Small-Cap Companies for 2025.\u003c\/h3\u003e\n\u003cp\u003e\nSustained recognition and financial performance demonstrate organizational effectiveness in leveraging niche leadership.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eForbes Rank: \u003cstrong\u003e24th\u003c\/strong\u003e on America's Most Successful Small-Cap Companies list for \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePrevious Forbes Rank: \u003cstrong\u003e59th\u003c\/strong\u003e on the \u003cstrong\u003e2024\u003c\/strong\u003e list.\u003c\/li\u003e\n\u003cli\u003eForbes Screening Universe: \u003cstrong\u003e914\u003c\/strong\u003e companies screened (for 2025 list).\u003c\/li\u003e\n\u003cli\u003eCompany Market Value Range Screened: Between \u003cstrong\u003e$300 million and $2 billion\u003c\/strong\u003e (for 2025 list).\u003c\/li\u003e\n\u003cli\u003eRegular Quarterly Cash Dividend: \u003cstrong\u003e$0.17\u003c\/strong\u003e per share declared for Q2 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage: Temporary; while strong now, a major competitor with deep pockets could eventually challenge the brand perception.\u003c\/h3\u003e\n\u003cp\u003e\nThe market is projected to grow to \u003cstrong\u003eUSD 571.11 million\u003c\/strong\u003e by \u003cstrong\u003e2030\u003c\/strong\u003e, attracting potential large-scale entrants.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Market Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 571.11 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2030 Projection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket CAGR\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024 to 2033 Forecast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Domestic Sales % of Total Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e85%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to \u003cstrong\u003e83%\u003c\/strong\u003e in Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eIRadimed Corporation (IRMD) - VRIO Analysis: High and Improving Gross Profit Margin\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Directly translates strong revenue growth into higher profitability, providing cash for reinvestment and dividends.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eQ3 2025 Revenue was \u003cstrong\u003e$21.2 million\u003c\/strong\u003e, a \u003cstrong\u003e16%\u003c\/strong\u003e increase year-over-year from Q3 2024 revenue of \u003cstrong\u003e$18.33 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eRegular quarterly cash dividend declared at \u003cstrong\u003e$0.17\u003c\/strong\u003e per share for the fourth quarter of 2025, payable on November 25, 2025.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; the Q3 2025 gross margin hit \u003cstrong\u003e78%\u003c\/strong\u003e, which is excellent for a medical device manufacturer.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025\u003c\/th\u003e\n\u003cth\u003eQ3 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e78%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e77%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Amount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; achieving this margin requires tight control over manufacturing costs and premium pricing power.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eThe \u003cstrong\u003e78%\u003c\/strong\u003e gross margin in Q3 2025 was achieved despite transitional inefficiencies from settling into the new Orlando facility early in the quarter.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eRevenue from 3860 MRI IV Pump Sales grew \u003cstrong\u003e20%\u003c\/strong\u003e in Q3 2025, with no revenue discounting.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; the margin remained high at \u003cstrong\u003e77%\u003c\/strong\u003e even during the transition to the new facility for the nine months ended September 30, 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003cth\u003eNine Months Ended September 30, 2025\u003c\/th\u003e\n\u003cth\u003eNine Months Ended September 30, 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e77%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e77%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$61.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$53.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; suggests superior cost structure or pricing power relative to peers in this specialized field.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eThe gross profit margin was \u003cstrong\u003e78%\u003c\/strong\u003e for Q3 2025, an increase from \u003cstrong\u003e77%\u003c\/strong\u003e in Q3 2024.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eThe company reported its seventeenth consecutive quarter of record revenue as of Q3 2025.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIRadimed Corporation (IRMD) - VRIO Analysis: New, Fully Operational Manufacturing Facility\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Removes capacity constraints, allowing the company to fulfill its all-time high backlog for both pump and monitor systems. The facility's operational status supported record financial performance in Q3 2025, despite transitional inefficiencies early in the quarter.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Temporary; building a facility is imitable, but the timing (fully operational as of the end of Q3 2025) is opportune, coinciding with the backlog reaching an all-time high for both pump and monitor systems.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy; the facility itself is a tangible asset. The total construction cost of the New Facility was approximately \u003cstrong\u003e$13.3 million\u003c\/strong\u003e. Final cash payments on the New Facility in Q3 2025 totaled approximately \u003cstrong\u003e$1.3 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; management successfully managed the move while maintaining high margins and reporting record revenue. This is evidenced by the company reporting its \u003cstrong\u003eseventeenth consecutive quarter of record revenue\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this asset primarily enables the exploitation of other advantages, such as meeting demand for products like the 3860 MRI IV pump, which grew \u003cstrong\u003e20%\u003c\/strong\u003e year-over-year in Q3 2025.\u003c\/p\u003e\n\u003cp\u003eKey financial metrics from the period surrounding the facility becoming fully operational (Q3 2025) are presented below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eComparison\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$21.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e16%\u003c\/strong\u003e increase compared to Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e78%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStrong margin despite transitional inefficiencies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP Diluted EPS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.43\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e8%\u003c\/strong\u003e increase compared to Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-GAAP Diluted EPS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.47\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e9%\u003c\/strong\u003e increase compared to Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income (GAAP)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from $5.0 million in Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull-Year 2025 Revenue Guidance (Raised)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$82.5 million to $83.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from prior guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOperational performance highlights supporting the organizational strength include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMRI compatible IV infusion pump systems revenue was \u003cstrong\u003e$8.3 million\u003c\/strong\u003e, up \u003cstrong\u003e20%\u003c\/strong\u003e year-over-year in Q3 2025.\u003c\/li\u003e\n\u003cli\u003ePatient vital signs monitoring systems revenue was \u003cstrong\u003e$6.9 million\u003c\/strong\u003e, up \u003cstrong\u003e16%\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eDisposable revenue grew \u003cstrong\u003e12%\u003c\/strong\u003e to \u003cstrong\u003e$4.1 million\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eThe company declared a regular quarterly cash dividend of \u003cstrong\u003e$0.17\u003c\/strong\u003e per share, payable on November 25, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIRadimed Corporation (IRMD) - VRIO Analysis: Strong Financial Performance and Growth Trajectory\n\u003c\/h2\u003e\n\n\u003cp\u003e\nThe financial performance and growth trajectory of IRadimed Corporation demonstrate significant tangible resources supporting its competitive position.\n\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\nProvides capital access, investor confidence, and the ability to fund R\u0026amp;D and shareholder returns.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nRaised full-year 2025 revenue guidance to \\$82.5 million to \\$83.5 million from \\$80.0 million to \\$82.5 million.\n\u003c\/li\u003e\n\u003cli\u003e\nDeclared a regular quarterly cash dividend of \\$0.17 per share.\n\u003c\/li\u003e\n\u003cli\u003e\nReported GAAP diluted earnings per share guidance raised to \\$1.68 to \\$1.72 for the full year 2025.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\nModerate; achieving 17th consecutive quarter of record revenue is impressive in the sector.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nReported record revenue for the 17th consecutive quarter in Q3 2025.\n\u003c\/li\u003e\n\u003cli\u003e\nQ3 2025 revenue was \\$21.2 million, a 16% increase year-over-year.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003e\nDifficult; replicating the 13% revenue growth for the nine months ended September 30, 2025 (to \\$61.1 million) is hard.\n\u003c\/p\u003e\n\u003cp\u003e\nKey financial metrics for the nine months ended September 30, 2025, compared to the prior year period:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eNine Months Ended Sept 30, 2025\u003c\/td\u003e\n\u003ctd\u003eNine Months Ended Sept 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$61.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$53.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$16.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$14.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP Diluted EPS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.25\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.10\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-GAAP Net Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$17.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$15.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nQ3 2025 operational performance:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Value\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$21.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e78%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP Diluted EPS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.43\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-GAAP Diluted EPS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.47\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003e\nStrong; management raised full-year 2025 revenue guidance to \\$82.5 million to \\$83.5 million.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nManagement raised full-year 2025 revenue guidance to \\$82.5 million to \\$83.5 million.\n\u003c\/li\u003e\n\u003cli\u003e\nFourth quarter 2025 revenue expected to be \\$21.4 million to \\$22.4 million.\n\u003c\/li\u003e\n\u003cli\u003e\nCash and cash equivalents ended at \\$56.5 million as of Q3 2025.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\nTemporary; sustained growth is hard to maintain, but the current momentum is a powerful resource.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nAnticipated limited commercial shipments of the 3870 MRI-compatible IV infusion pump in December, with full U.S. commercialization in Q1 2026.\n\u003c\/li\u003e\n\u003cli\u003e\nProjected pump revenue run rate approaching nearly \\$50 million annually with the 3870 pump sales.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIRadimed Corporation (IRMD) - VRIO Analysis: Robust Intellectual Property (IP) Portfolio\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eProtects the core technology from direct copying, securing the company's monopoly in key product segments, including the only known non-magnetic intravenous (IV) infusion pump system safe for MRI procedures and non-magnetic patient vital signs monitoring systems. The patented MRidium® MRI compatible IV infusion pump system features a non-magnetic ultrasonic motor and uniquely designed non-ferrous parts.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate; having enforceable patents in this niche is not common. As of September 2022, IRadimed had a total of 27 patents globally, out of which 23 had been granted, with more than 77% remaining active. This compares to a reported 17 total patents as of May 2020. The company's fiscal year 2024 revenue was $73.2 million.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Global Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e27\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGranted Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive Patents (Approximate)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e\u0026gt;77%\u003c\/strong\u003e of total\u003c\/td\u003e\n\u003ctd\u003eAs of September 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Patent Applications Granted Rate (Excluding subsidiaries)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e91.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAt USPTO, based on 11 granted out of 13 filed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$73.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year Ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eDifficult; defending and enforcing patent claims against infringement requires significant legal and technical resources. The company's patented technology includes systems for wirelessly communicating with and remotely controlling IV infusion pumps, such as patent number US 10,617,821 B2. The cost of obtaining a single patent family with coverage in the US, EU, and Japan can be around $100,000, with maintenance costs potentially reaching $75,000 over twenty years.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eModerate; management explicitly lists the ability to identify and pursue development of additional products and the protection of intellectual property rights on its products as key factors in its business strategy. The company's R\u0026amp;D focus is primarily centered in the United States of America.\u003c\/p\u003e\n\n\u003cp\u003eThe IP portfolio supports key product lines:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMRI Compatible IV Infusion Pumps (e.g., MRidium® 3860+)\u003c\/li\u003e\n\u003cli\u003eNon-Magnetic Patient Vital Signs Monitoring Systems (e.g., 3880)\u003c\/li\u003e\n\u003cli\u003eFMD Smart MRI Ferrous Metal Detector (with Trusense technology)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained; a strong, well-defended patent moat is the classic source of long-term advantage in med-tech, particularly given the company's position as the only known provider in its core niche.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIRadimed Corporation (IRMD) - VRIO Analysis: Established Shareholder Return Policy (Dividend)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eEstablished Shareholder Return Policy (Dividend)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Attracts a specific class of long-term, income-focused investors, stabilizing the stock base.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many growth-focused small-caps reinvest all cash, so a consistent dividend is a choice.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy; competitors can copy the dividend policy, but it requires consistent free cash flow.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; the regular quarterly cash dividend of \u003cstrong\u003e$0.17 per share\u003c\/strong\u003e demonstrates financial discipline.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; it's a policy choice that can be reversed if cash flow tightens unexpectedly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDividend History Data:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eEx-Date\u003c\/td\u003e\n\u003ctd\u003eCash Amount (Per Share)\u003c\/td\u003e\n\u003ctd\u003eFrequency\u003c\/td\u003e\n\u003ctd\u003eAnnual Dividend (Approximate)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovember 14, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.17\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarterly\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.68\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAugust 18, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.17\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarterly\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.68\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMay 20, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.17\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarterly\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.68\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFebruary 24, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.17\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarterly\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.68\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovember 15, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.15\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarterly\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0.60\u003c\/strong\u003e (Based on $0.15 x 4)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eSupporting Financial Metrics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMost recent quarterly cash dividend declared: \u003cstrong\u003e$0.17 per share\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnnual dividend per share: \u003cstrong\u003e$0.68\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMost recent annual dividend yield: \u003cstrong\u003e0.73%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDividend Payout Ratio based on trailing year earnings: \u003cstrong\u003e41.21%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDividend Payout Ratio based on cash flow: \u003cstrong\u003e42.70%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company has increased its dividend for \u003cstrong\u003e1 year\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePast year earnings per share: \u003cstrong\u003e$0.47\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe initiation of the regular quarterly dividend at \u003cstrong\u003e$0.15 per share\u003c\/strong\u003e was announced in December 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIRadimed Corporation (IRMD) - VRIO Analysis: High Product Backlog and Demand Visibility\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Provides high certainty for near-term revenue, making forecasting more reliable and reducing sales risk.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company has achieved fourteen consecutive quarters of record-breaking revenues as of the end of 2024. Orders booked in the fourth quarter of 2024 exceeded shipments, establishing a robust backlog that enhances visibility entering 2025. The full-year 2025 revenue guidance is projected between $78.0 million and $82.0 million, which was later raised to $80 million to $82.5 million based on Q2 2025 results.\u003c\/p\u003e\n\n\u003cp\u003e\u003ch\u003e\u003ch\u003eFinancial Metrics Supporting Demand Visibility\u003c\/h\u003e\u003c\/h\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003cth\u003eAmount\/Range\u003c\/th\u003e\n\u003cth\u003eYoY Change\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreliminary Revenue\u003c\/td\u003e\n\u003ctd\u003eQ4 2024\u003c\/td\u003e\n\u003ctd\u003eApproximately $19.2 million to $19.4 million\u003c\/td\u003e\n\u003ctd\u003e10% to 11% increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreliminary Revenue\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003ctd\u003eApproximately $73.1 million to $73.3 million\u003c\/td\u003e\n\u003ctd\u003e11% to 12% increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e$20.4 million\u003c\/td\u003e\n\u003ctd\u003e14% increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePump Order Backlog Duration\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e5-6 months\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: High; having an all-time high backlog for both pump and monitor systems signals exceptional current demand.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company is the only known provider of non-magnetic intravenous (IV) infusion pump systems and non-magnetic patient vital signs monitoring systems designed for use during MRI procedures. Management noted a strong backlog for both pumps and monitors providing solid visibility for the first half of 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Difficult; a backlog this large is a direct result of the rare, in-demand products they sell.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe premier product, an IV pump for use in the MRI, is stated as the only one like it in the world. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss. The new 3870 MR IV pump system received FDA clearance.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Strong; the new facility was built specifically to address this backlog, showing organizational alignment with demand.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization is expanding its physical capacity to meet demand:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBuilding a state-of-the-art 60,000-square-foot facility at the Central Florida Research Park.\u003c\/li\u003e\n\u003cli\u003eAnticipates spending approximately $5.5 million in cash in 2025 to complete the project. The total investment is $20 million.\u003c\/li\u003e\n\u003cli\u003eConstruction completion was targeted for mid-year 2025, with specific mentions of June 2025 or May 2025.\u003c\/li\u003e\n\u003cli\u003eThe expansion is creating 160 new jobs with an average wage of $85,000.\u003c\/li\u003e\n\u003cli\u003eThe sales force plan includes expansion from 28 to 35 territories by 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained; as long as the need for safe MRI procedures remains, this demand signal will persist.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company projects replacement demand for pumps starting in 2026 of 800-1,000 systems annually, potentially doubling current pump sales. The 3860 orders remain strong, expected to continue until the promotion of the 3,870 begins in December. The company anticipates a revenue run rate of $100 million by the end of 2026.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance: draft Q4 2025 cash flow projection incorporating the new facility's full operational costs by Friday.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company reported a quarterly cash dividend increase to $0.17 per share from $0.15 per share. For the year ended December 31, 2024, domestic sales were 83% of total revenue. The gross profit margin for the year ended December 31, 2024, was 76.9%. Operating expenses increased to $9 million in Q4 2024.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516189368469,"sku":"irmd-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/irmd-vrio-analysis.png?v=1740186271","url":"https:\/\/dcf-model.com\/products\/irmd-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}